PeptideCompareAdipotide — EU research guide.
Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a proapoptotic peptide that selectively induces apoptosis in the blood vessels feeding white adipose tissue, reducing fat mass in preclinical models.
What is Adipotide?
Adipotide is a targeted peptide consisting of a homing domain (CKGGRAKDC) that binds to ANXA2/prohibitin receptors on adipose vasculature, linked to a pro-apoptotic domain (D(KLAKLAK)2). Upon binding it triggers mitochondrial disruption in endothelial cells feeding fat tissue, causing selective adipose reduction in animal models.
What does the research show?
In obese non-human primates (rhesus monkeys), Adipotide produced ~11% body weight reduction and ~30% reduction in BMI over 28 days. Kidney toxicity was observed at higher doses, which has limited clinical development. No human clinical trials have been completed. All data is animal-derived.
EU legal status
Adipotide has no approved status anywhere. It is an experimental research compound with a kidney toxicity signal observed in primate studies. It is sold for preclinical laboratory research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Computed from molecular properties (sequence length, cyclisation, residues prone to oxidation or deamidation, light sensitivity), per compound. Indicative only — not lab-measured per batch.
Adipotide across EU suppliers
COA-verified EU vendors · Updated monthly